Abstract
Little data are available concerning the molecular mechanisms of action of Brca1 and Brca2 in breast oncogenesis. Recent experimental results suggest that Brca1 plays a role in the regulation of apoptosis. In order to determine whether the analysis of human tumours would provide data supporting this hypothesis, we have assessed the expression of the antiapoptotic bcl-2 and of the proapoptotic p53 genes in Brca1- and Brca2-associated breast carcinomas. The levels of expression of these genes were compared to those observed in controls and to the mitotic and the apoptotic indexes. Our series were composed of 16 cases of breast carcinoma in women with a germline Brca1 gene mutation, and of four cases with Brca2 mutation. A group of 39 patients aged under 36 years and for whom the search for Brca1 gene mutations was negative, and a group of 36 cases of sporadic cancers without data on their Brca status were used as controls. Immunohistochemistry was used to detect p53 and bcl-2 gene products. Mitotic and apoptotic indexes were higher in Brca1-associated tumours than in controls. No significant difference in p53 immunostaining was observed between the four groups of patients. In contrast, the rate of bcl-2-positive tumours was lower (31%) in Brca1-carcinomas than in carcinomas without Brca1 mutation (90%) (P < 10–3). A strong Bcl-2 expression was found in the four cases of Brca2-associated carcinomas. No significant correlation was observed between p53 and Bcl-2 immunostainings, either in cases or in controls. The association between Brca1 status and Bcl-2 expression remained significant after adjustment for the oestrogen receptor status. Our study shows that a low expression of bcl-2 characterises most Brca1-associated breast carcinomas, a biological trait which seems not to be shared by Brca2-associated tumours nor to be related to oestrogen receptor and/or p53 status. bcl-2 might thus be one of the target genes involved in the oncogenesis related to Brca1 and its down-regulation may account for the increased apoptosis and the high proliferative rate observed in Brca1-associated carcinomas. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Agnarsson B, Jonasson J, Bjornsdottir I, Barkardottir R, Egilsson V and Sigurdsson H (1998) Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 47: 121–127
Ansquer Y, Gautier C, Fourquet A, Asselain B and Stoppa-Lyonnet D the Institut Curie Breast Cancer Group (1998) Survival in early-onset BRCA1-cancer patients. Lancet 352: 541
Armes J, Trute L, White D, Southey C, Hammet F, Tesoriero A, Hutchins A, Dite G, McCredie M, Giles G, Hopper J and Venter D (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59: 2011–2017
Barghava V, Kell D, van de Rijn M and Warnke R (1994) Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145: 535–540
Berardo M, Elledge R, de Moor C, Clark G, Osborne K and Allred C (1998) bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82: 1296–1302
Bessis M (1964) Studies on cell agony and death: an attempt at classification. In Ciba Foundation Symposium on Cellular Injury, A VS de Reuck, J Knight (eds). J & A Churchill Ltd: London
Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Lavaut M-N and Allasia C (1997) Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas. Br J Cancer 76: 340–346
Crook T, Crossland S, Crompton M, Osin P and Gusterson B (1997) p53 mutations in BRCA 1-associated familiar breast cancer. Lancet 350: 638–639
Cummings M, Winterford C and Walker N (1997) Apoptosis. Am J Surg Pathol 21: 88–101
Dowsett M, Smith I, Powles T, Salter J, Ellis P, Johnston S, Makris A, Mainwaring P, Gregory R, Archer C, Chang J and Assersohn L (1999) Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital experience. ESO Scientific Updates, Vol 4. Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects, A Howell, M Dowsett (eds) 113–125, Elsevier Science: London
Elston C and Ellis I (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 19: 403–410
Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P, Bishop D, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare M, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck T, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder B, Gayther S, Birch J, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott R, Maugard C, Vasen H, Seitz S, Cannon-Albright L, Schofield A, Zelada-Hedman M and Consortium BCL (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62: 676–689
Gee J, Robertson J, Ellis I, Willsher P, McClelland R, Hoyle H, Kyme S, Finlay P, Blamey R and Nicholson R (1994) Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Intl J Cancer 59: 619–628
Genestie C, Zafrani B, Asselin B, Fourquet A, Rozan S, Validire P, Vincent-Salomon A and Sastre-Garau X (1998) Comparison of the respective prognostic values of Scarff-Bloom-Richardson and Nottingham histological grade in a series of 825 cases of breast cancer. Major importance of the mitotic count as a component of both grading systems. Anticancer Res 18: 571–576
Gudas J, Li T, Nguyen H, Jensen D, Rauscher F and Cowan K (1996) Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ 7: 717–723
Hartmann A, Blaszyk H, Kovach J and Sommer S (1997) The molecular epidemiology of P53 gene mutations in human breast cancer. Trends Genet 13: 27–33
Hellemans P, van Dam P, Weyler J, van Oosterom A, Buytaert P and Van Marck E (1995) Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354–360
Huang D, O'Reilly L, Strasser A and Cory S (1997) The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 16: 4628–4638
Jacquemier J, Eisinger F, Birnbaum D and Sobol H (1995) Histoprognostic grade in BRCA1-associated breast cancer. Lancet 345: 1503
Joensuu H, Pylkkänen L and Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145: 1191–1198
Lakhani S, Jacquemier J, Sloane J, Gusterson B, Anderson T, van de Vijver M, Farid L, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel M, Haites N, Scott R, Goldgar D, Neuhausen S, Daly P, Ormiston W, McManus R, Scherneck S, Ponder B, Ford D, Peto J, Stoppa-Lyonnet D, Bignon Y, Struewing J, Spurr N, Bishop D, Devilee P, Cornelisse C, Lasset C, Lenoir G, Bjork Barkardottir R, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton M and Easton D (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90: 1338–1345
Leek R, Kaklamanis L, Pezzella F, Gatter K and Harris A (1994) bcl-2 in normal breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135–139
O'Reilly L, Huang D and Strasser A (1996) The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 15: 6979–6990
Robson M, Rajan P, Rosen P, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L and Offit K (1998) BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 58: 1389–1842
Schlichtholz B, Bouchind'homme B, Pages S, Martin E, Liva S, Magdelenat H, Sastre-Garau X, Stoppa-Lyonnet D and Soussi T (1998) p53 mutations in BRCA1-associated familial breast cancer. Lancet 352: 622
Silvestrini R, Benini E, Veneroni S, Daidone M, Tomasic G, Squicciarini P and Salvadori B (1996) p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604–1610
Silvestrini R, Veneroni S, Daidone M, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499–504
Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173–182
van Slooten H-J, van de Vijver M, van de Velde C and van Dierendonck J (1998) Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, by also with increased proliferative activity. Br J Cancer 77: 789–796
Xu X, Wagner K, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A and Deng C (1999) Conditional mutation of Brcal in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genet 22: 37–43
Yang X and Lippman M (1999) BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat 54: 1–10
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Freneaux, P., Stoppa-Lyonnet, D., Mouret, E. et al. Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 83, 1318–1322 (2000). https://doi.org/10.1054/bjoc.2000.1438
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1438
Keywords
This article is cited by
-
Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
Oncogene (2016)
-
NF-κB is a critical mediator of BRCA1-induced chemoresistance
Oncogene (2014)
-
Phenotype-Genotype Correlation in Familial Breast Cancer
Journal of Mammary Gland Biology and Neoplasia (2011)
-
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers
Breast Cancer Research and Treatment (2011)
-
Pathology of hereditary breast cancer
Cellular Oncology (2011)